- Question from Sprph: Is there any advantage to 12 weeks of Taxol vs. 4 weeks of dose-dense Taxol?
There are studies investigating the best way of giving Taxol and the related drug Taxotere. For now, we know that these drugs are very important in women at high risk of recurrent disease.
On the other hand, for many patients, these drugs are not necessary. We are always trying to improve treatment of breast cancer, and it seems as though the progress is occurring at a faster and faster pace. Again, clinical trials are underway to answer your question.
- New Breast Cancer Progression Model Developed Stay tuned!
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.